Dr. Saurav Mishra

Designation: Assistant Professor

Medical Reg. No.: HPR-ID- 71-0372-0116-6820

Departments: Pharmacology

Educational Qualification

Education

PG

Area Of Interest

Area Of Interest

Pharmacology

Publications

1. Atal S, Jhaj R, Mathur A, Rai N, Misra S, Sadasivam B. Outpatient prescribing trends, rational use of medicine and impact of prescription audit with feedback at a tertiary care centre in India. Int J Health Plann Manage. 2021 Jan 25. 2. Shukla AK, Misra S. Clinical inertia in elderly for vaccination. J Family Med Prim Care. 2021 3. Shukla AK, Misra S. Antiviral Effects of Ivermectin in COVID-19- Clinically Plausible. International journal of infectious disease. 2021 4. Shukla AK, Jhaj R, Misra S, Ahmad SN, Nanda M, Chaudhary D. Agreement between WHO-UMC Causality scale and the Naranjo Algorithm for Causality Assessment of Adverse Drug Reactions. J Family Med Prim Care. 2021 5. Atal S, Misra S, Balakrishnan S. Continued use of azithromycin for mild COVID-19 in India: evidence and implications?. J Family Med Prim Care. 2021. 6. Atal S, Joshi R, Misra S, Fatima Z, Sharma S, Balakrishnan S. Patterns of drug therapy, glycaemic control and predictors of escalation - non escalation of treatment among diabetes outpatients at a tertiary care centre. Journal of Basic and Clinical Physiology and Pharmacology. 2021 7. Shukla AK, Misra S. Antibody-dependent enhancement of virus infection and disease: Implications in COVID-19. 2021 Misra S, Kaushal J, Khurana AK. A Study Of Efficacy And Safety Of Loteprednol Versus Cyclosporine As An Add On Therapy To Carboxymethyl Cellulose In Comparison To Carboxymethyl Cellulose As Monotherapy In Dry Eye Disease. World Journal Of Pharmacy And Pharmaceutical Sciences.2018;7(3):915-26 (7.421) Misra S, Kaushal J.Treatment Compliance Among Open Angle Glaucoma Patients At Tertiary Care Centre In Northern India. European Journal Of Pharmaceutical And Medical Research. 2018,5(4), 500-505 (UNDER PRECESS) (4.897 ) Misra S, Kaushal J, Khurana AK. Quality Of Life With Three Schedules In Dry Eye Disease Patients: A Comparative Study. European Journal Of Pharmaceutical And Medical Research. 2019;6(6):682-8. (UNDER PRECESS) (4.897 ) Atal S, Misra S, Balakrishnan S. Continued use of azithromycin for mild COVID-19 in India: evidence and implications?. J Family Med Prim Care. 2021. Shukla AK, Misra S. An overview of post COVID sequelae. J Basic Clin Physiol Pharmacol. 2022 Apr 15. doi: 10.1515/jbcpp-2022-0057. Epub ahead of print. PMID: 35428040. (Accepted on 23rd March 2022). Shukla AK, Misra. Antimicrobials in COVID-19: Strategies for treating a COVID-19 Pandemic. J Basic Clin Physiol Pharmacol. 2022 (Accepted on 31st March 2022). Shukla AK, Misra S, Atal S. Ivermectin in Mild COVID-19: Panoramic Evaluation of the Evidence. 2022. Current Aspects in Pharmaceutical Research and Development Vol. 9, 130–136. https://doi.org/10.9734/bpi/caprd/v9/15204D Shukla AK, Misra S, Atal S. Continued Use of Hydroxychloroquine for COVID-19 in Outpatient or Hospitalized Settings: What is the Evidence?. 2022. Current Aspects in Pharmaceutical Research and Development Vol. 9, 137–143. https://doi.org/10.9734/bpi/caprd/v9/15205D. Misra, S, Shukla, A. K. (2022). Medical Student Education in the Time of SARSCoV-2 Pandemic: Indian Scenario. Emerging Trends in Disease and Health Research Vol. 7, 21 April 2022, Page 85-89. https://doi.org/10.9734/bpi/etdhr/v7/2505C (Accepted on 12th March 2022). Misra, S, Shukla, A. K. (2022). Clinical implications of Anti-idiotype Antibodies in COVID-19. Journal- Journal of Basic and Clinical Physiology and Pharmacology (JBCPP). Accepted on 4th October 2022 (review article). Shukla AK, Misra S. Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. N Engl J Med. 2022 Dec 15;387(24):e65. Shukla AK, Misra S. A review of Monkeypox disease and future treatment options. Int. J. Curr. Pharm. 2023;23(1): Shukla AK, Misra S. Novel entry inhibitors for Viral Hepatitis D treatment : Bulevirtide. Int. J. Curr. Pharm. 2023;23(1): Shukla AK, Misra S. Bispecific antibodies and its applications: a novel approach for targeting SARS-Cov-2. J Basic Clin Physiol Pharmacol. 2023 Misra S, Shukla AK. Tepizumab: type 1 diabetes mellitus preventable: European Journal of Clinical Pharmacology 79 (5), 609-616,2023. Shukla AK, Misra S. COVID-19 Infection and Vaccination in Pregnancy: A Review. Int. J. Curr. Pharm. Res. 2023.15;(5):39-44 Shukla AK, Misra S. Tecovirimat: A comprehensive review of Novel drug for Monkeypox disease. Int. J. Curr. Pharm. 2023.15;(5):45-49 Deb T, Misra S, Sindhu N, Beni R. Deb’s Active Surveillance & Assisted Reporting System: a district based innovative approach to adverse drug reaction monitoring. International Journal of Toxicological And Pharmacological Research (Ijtpr) (Accepted As On 17 Th September)